Noam E. Kopmar

Also affiliated with Fred Hutch Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL”.

Phase 1 study of CD19 CAR T-cell therapy harboring a fully human scFv in CAR-naïve adult patients with B-ALL

Blood Advances(2025)10.1182/bloodadvances.2024015314

N/A

0.447DataRank · unranked

10 citations

Emily C. Liang, Jennifer J. Huang, Erik L. Kimble, Alexandre V. Hirayama, Salvatore Fiorenza +15 more

Development and validation of predictive models of early immune effector cell–associated hematotoxicity

Blood Advances(2024)10.1182/bloodadvances.2024014455

N/A

0.360DataRank · unranked

10 citations

Jennifer J. Huang, Andrew J. Portuguese, Valentín Ortiz‐Maldonado, Aya Albittar, Natalie Wuliji +28 more

CAR HEMATOTOX independently predicts outcomes after CD19 CAR-T therapy for acute lymphoblastic leukemia

Blood Advances(2025)10.1182/bloodadvances.2025017526

N/A

0.267DataRank · unranked

3 citations

Chenyu Lin, David Nemirovsky, Sean Devlin, Kai Rejeski, Kevin J. Curran +43 more

A phase I trial of dose-adjusted EPOCH plus inotuzumab ozogamicin (InO) in adults with relapsed/refractory (R/R) B lymphoblastic leukemia/lymphoma (B-ALL).

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.16_suppl.7007

N/A

0.104DataRank · unranked

1 citations

Kim Quach, Ted Gooley, Christen H. Martino, Sindhu Cherian, Mary‐Elizabeth M. Percival +8 more